Compare PMCB & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMCB | NXL |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 8.3M |
| IPO Year | 2001 | N/A |
| Metric | PMCB | NXL |
|---|---|---|
| Price | $0.75 | $0.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 101.5K | ★ 414.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 277.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | N/A | $185.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $0.37 |
| 52 Week High | $1.82 | $2.57 |
| Indicator | PMCB | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 39.48 |
| Support Level | $0.66 | $0.37 |
| Resistance Level | $1.05 | $0.62 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 84.26 | 29.08 |
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.